Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed its Q1 2018 10-Q quarterly report on May 3, 2018 for the quarter ended Mar 31, 2018.
Teva Pharmaceutical Industries Ltd Q1 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $5.1B, down 10% YoY from Q1 2017, or 15% in local currency
- Gross margin 46.4% vs 50.2%; operating margin 30.0% vs 15.8%
- Best segment: Europe revenue $1.4B, up 8%, profit $377M, up 41%; worst: North America revenue $2.5B, down 22%, profit $915M, down 30%
- Operating cash flow $1.5B vs $0.1B; cash and investments $1.5B vs $1.1B; debt $30.8B vs $32.5B
- Headwinds: U.S. generics price erosion and COPAXONE competition; 2018 non-GAAP tax rate expected at 17%
Risk Factors
- New opioid litigation risk: DOJ subpoena dated April 27, 2018 and multidistrict litigation first trial set for March 2019
- Regulatory and compliance exposure: Illinois Medicaid case seeks approximately $90 million damages plus statutory penalties of $362 million to approximately $1.2 billion
- Competitive risk: North America revenues fell 22% amid adverse U.S. generics dynamics and COPAXONE generic competition
- Financial risk: March 31 debt included $29.45 billion senior notes and loans, with 64% effectively denominated in U.S. dollars
- Legal risk: Ception shareholders seek at least $200 million over alleged failure to develop CINQAIR for eosinophilic esophagitis
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teva Pharmaceutical Industries Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.